دورية أكاديمية
أعرض في EDS

Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.

التفاصيل البيبلوغرافية
العنوان: Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
المؤلفون: Barry EL; Department of Community and Family Medicine, Dartmouth Medical School, Suite 300, Evergreen Center, 46 Centerra Parkway, Lebanon, NH 03756, USA. Elizabeth.L.Barry@Dartmouth.edu, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA
المصدر: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2009 Oct; Vol. 18 (10), pp. 2726-33. Date of Electronic Publication: 2009 Sep 15.
نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9200608 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7755 (Electronic) Linking ISSN: 10559965 NLM ISO Abbreviation: Cancer Epidemiol Biomarkers Prev Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : American Association for Cancer Research, c1991-
مواضيع طبية MeSH: Adenoma/*prevention & control , Aspirin/*administration & dosage , Colorectal Neoplasms/*prevention & control , Cyclooxygenase 2/*genetics , Cyclooxygenase 2 Inhibitors/*administration & dosage , Neoplasm Recurrence, Local/*prevention & control, Adenoma/enzymology ; Adenoma/genetics ; Aged ; Cohort Studies ; Colorectal Neoplasms/enzymology ; Colorectal Neoplasms/genetics ; Female ; Folic Acid/genetics ; Folic Acid/therapeutic use ; Gene Frequency ; Genetic Variation ; Genotype ; Haplotypes ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/enzymology ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Polymorphism, Genetic ; Polymorphism, Single Nucleotide ; Risk Assessment
مستخلص: Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in the production of prostaglandins, potent mediators of inflammation. Chronic inflammation plays an important role in the development and progression of colorectal cancer. Aspirin inhibits COX-2 activity and lowers the risk for colorectal adenomas and cancer. We investigated whether common genetic variation in COX-2 influenced risk for colorectal adenoma recurrence among 979 participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or aspirin and followed for 3 years for the occurrence of new adenomas. Of these participants, 44.2% developed at least one new adenoma during follow-up. Adjusted relative risks and 95% confidence intervals (95% CI) were calculated to test the association between genetic variation at six COX-2 single-nucleotide polymorphisms and adenoma occurrence and interaction with aspirin treatment. Two single-nucleotide polymorphisms were significantly associated with increased adenoma recurrence: for rs5277, homozygous carriers of the minor C allele had a 51% increased risk compared with GG homozygotes (relative risk, 1.51; 95% CI, 1.01-2.25), and for rs4648310, heterozygous carriers of the minor G allele had a 37% increased risk compared with AA homozygotes (relative risk, 1.37; 95% CI, 1.05-1.79). (There were no minor allele homozygotes.) In stratified analyses, there was suggestive evidence that rs4648319 modified the effect of aspirin. These results support the hypothesis that COX-2 plays a role in the etiology of colon cancer and may be a target for aspirin chemoprevention and warrant further investigation in other colorectal adenoma and cancer populations.
References: Nutr Rev. 2007 Dec;65(12 Pt 2):S157-66. (PMID: 18240541)
Gastroenterology. 1994 Oct;107(4):1183-8. (PMID: 7926468)
N Engl J Med. 2000 Jul 13;343(2):78-85. (PMID: 10891514)
J Biol Chem. 2000 Oct 27;275(43):33951-6. (PMID: 10930401)
Anticancer Res. 2008 Sep-Oct;28(5B):3119-23. (PMID: 19031967)
Mol Biol Evol. 1995 Sep;12(5):921-7. (PMID: 7476138)
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):616-9. (PMID: 15767339)
Cancer Sci. 2008 Mar;99(3):576-81. (PMID: 18167131)
J Natl Cancer Inst. 2006 Oct 18;98(20):1494-500. (PMID: 17047198)
Bioinformatics. 2005 May 1;21(9):2128-9. (PMID: 15705655)
J Clin Oncol. 2005 Apr 20;23(12):2840-55. (PMID: 15837998)
Br J Cancer. 2005 Oct 17;93(8):953-9. (PMID: 16205694)
Br J Cancer. 2004 May 4;90(9):1760-4. (PMID: 15150618)
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1305-15. (PMID: 12433707)
Am J Gastroenterol. 2002 Apr;97(4):1037-41. (PMID: 12003384)
Pharmacogenomics J. 2008 Aug;8(4):237-47. (PMID: 18195728)
Int J Cancer. 2006 Jul 15;119(2):297-303. (PMID: 16482563)
Ann Intern Med. 2007 Mar 6;146(5):376-89. (PMID: 17339623)
Clin Cancer Res. 2004 Dec 15;10(24):8465-71. (PMID: 15623626)
Nat Rev Cancer. 2006 Feb;6(2):130-40. (PMID: 16491072)
Cancer Res. 1995 Sep 1;55(17):3785-9. (PMID: 7641194)
Lancet. 2007 May 12;369(9573):1603-13. (PMID: 17499602)
N Engl J Med. 2007 May 24;356(21):2131-42. (PMID: 17522398)
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1126-31. (PMID: 16775170)
Biochem Pharmacol. 2005 Oct 1;70(7):969-86. (PMID: 15949789)
Obstet Gynecol. 2007 Feb;109(2 Pt 1):384-91. (PMID: 17267840)
World J Gastroenterol. 2008 Mar 21;14(11):1785-9. (PMID: 18350611)
N Engl J Med. 2006 Aug 31;355(9):873-84. (PMID: 16943400)
Gastroenterology. 2006 Dec;131(6):1674-82. (PMID: 17087947)
FASEB J. 1998 Sep;12(12):1063-73. (PMID: 9737710)
Nat Rev Genet. 2009 Jun;10(6):353-8. (PMID: 19434079)
Clin Cancer Res. 2009 Apr 1;15(7):2559-66. (PMID: 19318492)
N Engl J Med. 2003 Mar 6;348(10):883-90. (PMID: 12621132)
Cancer. 2000 Dec 15;89(12):2637-45. (PMID: 11135226)
Cancer Causes Control. 2006 Apr;17(3):257-66. (PMID: 16489533)
JAMA. 1999 Oct 6;282(13):1254-7. (PMID: 10517428)
Eur J Gastroenterol Hepatol. 2009 Jan;21(1):76-91. (PMID: 19060633)
Nature. 2008 Jul 24;454(7203):436-44. (PMID: 18650914)
Pharmacogenet Genomics. 2006 Jan;16(1):43-50. (PMID: 16344721)
Ann Intern Med. 2007 Mar 6;146(5):365-75. (PMID: 17339622)
Bioinformatics. 2005 Jan 15;21(2):263-5. (PMID: 15297300)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
Carcinogenesis. 2007 Jun;28(6):1259-63. (PMID: 17277229)
N Engl J Med. 2008 Nov 13;359(20):2143-53. (PMID: 19005198)
Cancer Lett. 2008 Aug 28;267(2):197-203. (PMID: 18406516)
JAMA. 2007 Jun 6;297(21):2351-9. (PMID: 17551129)
J Cell Physiol. 2002 Mar;190(3):279-86. (PMID: 11857443)
N Engl J Med. 2003 Mar 6;348(10):891-9. (PMID: 12621133)
Br J Cancer. 2000 Aug;83(3):324-8. (PMID: 10917546)
Br J Cancer. 2004 Jul 19;91(2):339-43. (PMID: 15173859)
N Engl J Med. 2006 Aug 31;355(9):885-95. (PMID: 16943401)
Carcinogenesis. 2007 Jun;28(6):1197-201. (PMID: 17151091)
Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):147-54. (PMID: 17164142)
Adv Clin Chem. 2007;43:59-78. (PMID: 17249380)
Carcinogenesis. 2004 Dec;25(12):2467-72. (PMID: 15308583)
معلومات مُعتمدة: CA-059005 United States CA NCI NIH HHS; R01 CA059005-06A1 United States CA NCI NIH HHS; R01 CA059005-11A2 United States CA NCI NIH HHS; P30 CA023108 United States CA NCI NIH HHS; R01 CA059005-14 United States CA NCI NIH HHS; HHSN261200800001C United States CA NCI NIH HHS; R01 CA059005 United States CA NCI NIH HHS; HHSN261200800001E United States CA NCI NIH HHS; R01 CA059005-13 United States CA NCI NIH HHS; R01 CA059005-12 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Cyclooxygenase 2 Inhibitors)
935E97BOY8 (Folic Acid)
EC 1.14.99.1 (Cyclooxygenase 2)
R16CO5Y76E (Aspirin)
تواريخ الأحداث: Date Created: 20090917 Date Completed: 20100216 Latest Revision: 20240615
رمز التحديث: 20240615
مُعرف محوري في PubMed: PMC2769932
DOI: 10.1158/1055-9965.EPI-09-0363
PMID: 19755647
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-7755
DOI:10.1158/1055-9965.EPI-09-0363